Evidence map›Paper›PMID 38824485›Full record

ArticleJournal of thrombosis and thrombolysis2024

Cerebral venous sinus thrombosis associated with cancer: analysis of the ACTION-CVT study.

Maria Cristina Vedovati, Liqi Shu, Nils Henninger, Adeel S Zubair, Mirjam R Heldner, Sami Al Kasab, James E Siegler, David S Liebeskind, Kateryna Antonenko, Shadi Yaghi and 1 more

Abstract read
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Cerebrovascular and Peripheral Vascular Complications in Cancer Patients.Current neurology and neuroscience reports · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maria Cristina VedovatiDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy. mariacristina.vedovati@unipg.it.ORCID http://orcid.org/0000-0002-2268-9983
Liqi ShuDepartment of Neurology, Brown University, Providence, RI, USA.
Nils HenningerDepartment of Neurology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Adeel S ZubairDepartment of Neurology, Yale University, New Haven, CT, USA.
Mirjam R HeldnerDepartment of Neurology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
Sami Al KasabDepartment of Neurology, Medical University of South Carolina, Charleston, SC, USA.
James E SieglerCooper Neurological Institute, Cooper University, Camden, NJ, USA.
David S LiebeskindDepartment of Neurology, University of California at Los Angeles, Los Angeles, CA, USA.
Kateryna AntonenkoDepartment of Neurology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
Shadi YaghiDepartment of Neurology, Brown University, Providence, RI, USA.
Maurizio PaciaroniDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Nearly one fifth of patients with venous thromboembolism (VTE) have cancer. When both of these conditions occur, especially in cases of cerebral vein thrombosis (CVT), patient management is often challenging. The aim of this study was to compare the characteristics and event courses in patients affected by CVT with and without cancer. Consecutive patients with CVT from the ACTION-CVT cohort study were included if cancer status was reported. Risk factors as well as the clinical and radiological characteristics of patients were compared. Univariable and multivariable analyses were performed to assess variables associated with cancer. Kaplan-Meier method and log-rank test, logistic regression analysis, and propensity score matching were used to investigate any association between cancer-related CVT and study outcomes (primary outcome at 3-months: recurrent VTE or major hemorrhage; recurrent VTE; major hemorrhage; recanalization status; all-cause-death). Overall, 1,023 patients with CVT were included, of which 6.5% had cancer. Older age (adjusted odds ratio [aOR] 1.28 per decade increase; 95% confidence interval [CI] 1.08-1.52) and absence of headache (aOR 0.47; 95% CI 0.27-0.84) were independently associated with cancer. Patients with cancer had a higher risk of recurrent VTE or major hemorrhage (aOR 3.87; 95% CI 2.09-7.16), all-cause-death (aOR 7.56 95% CI 3.24-17.64), and major hemorrhage (aOR 3.70 95% CI 1.76-7.80). Recanalization rates, partial or complete, was not significantly different. CVT patients with cancer were more likely to be older, have no referred headache, and have worse outcomes compared to CVT patients without cancer.

Indexed as

NeoplasmsSinus Thrombosis, IntracranialAdultAgedAge FactorsCohort StudiesFemaleHemorrhageHumansMaleMiddle AgedRecurrenceRisk FactorsVenous ThromboembolismCancerCerebral venous thrombosisDirect oral anticoagulantsDOACVitamin K antagonists

Identifiers

PMID38824485
PMCPMC11315801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.